These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 28457854)

  • 1. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
    Zhang J; Wei Q; Dong D; Ren L
    Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
    Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
    Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
    Bozkurt M; Yumru AE; Aral I
    Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
    Yang J; Tang A; Ma J; Sun X; Ming L
    Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
    Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
    Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
    Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
    Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
    Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
    Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
    Jiang XP; Yang DC; Elliott RL; Head JF
    Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
    D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
    Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
    Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
    Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
    Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
    Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
    Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.